Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9BXT6

UPID:
M10L1_HUMAN

ALTERNATIVE NAMES:
Moloney leukemia virus 10-like protein 1

ALTERNATIVE UPACC:
Q9BXT6; A7E211; A8MXC6; B7WPP1; B7Z7R1; F5H403; Q5TGD5; Q8NBD4; Q9NXW3; Q9UFB3; Q9UGX9

BACKGROUND:
The RNA helicase Mov10l1, alternatively named Moloney leukemia virus 10-like protein 1, is indispensable for maintaining germline integrity. It suppresses transposable elements during meiosis by engaging in the piRNA metabolic process, forming complexes with piRNAs and Piwi proteins to mediate transposon methylation and repression. Its ATP-dependent RNA helicase activity enables the unwinding of RNA, facilitating the generation of piRNA precursors.

THERAPEUTIC SIGNIFICANCE:
Mov10l1's involvement in Spermatogenic failure 73, characterized by non-obstructive azoospermia due to meiotic arrest, highlights its significance in male fertility. Exploring Mov10l1's function offers promising avenues for developing targeted therapies for infertility.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.